Supriya Lifescience has scheduled its 18th Annual General Meeting (AGM) for Thursday, September 24, 2026. The meeting will be conducted through Video Conferencing or Other Audio Video Means (OAVM). The Board of Directors recommended a final dividend of Re. 1.00 per equity share for FY26 during its meeting on May 27, 2026. This proposal is subject to shareholder ratification at the AGM.

Financial Performance

FY26 marked the company's highest-ever annual revenue and EBITDA. Revenue from operations grew 18.9% year-on-year to ₹8,278.75 crore. Profit after tax increased 11.2% to ₹2,091.20 crore. EBITDA rose 12.8% to ₹294.1 crore, with margins at 35.5%. The company delivered strong demand across core therapeutic segments, supported by backward integration and disciplined execution.

Dividend Details

The final dividend will be paid within 30 days of the AGM, provided it receives member approval. Eligibility is determined by the names appearing in the Register of Members as on the record date of September 4, 2026. The dividend payout represents an outflow of ₹80.48 million.

Strategic Updates

Backward-integrated products accounted for 76% of revenue, supporting cost competitiveness. The company successfully completed an unannounced USFDA inspection at its Lote facility in February 2026, receiving its Establishment Inspection Report with one minor observation. Capital expenditure of ₹152 crore was directed largely towards the Ambernath facility, which extends manufacturing into formulations and contract manufacturing.

Board Re-appointments

Shareholders will vote on the re-appointment of Dr. Saloni Satish Wagh and Ms. Shivani Satish Wagh, who retire by rotation. Dr. Saloni Wagh serves as Managing Director, overseeing export, marketing, and business development. She holds a PhD in Chemistry and has been associated with the company since 2014. Ms. Shivani Wagh serves as Joint Managing Director, focusing on exports to Europe. She holds a master's degree in international business management from the University of Manchester. Both directors attended four board meetings in FY25-26 and hold 1,02,375 shares each (0.13%).

Special Business

The AGM agenda includes ratifying the remuneration of Cost Auditors for FY 2026-27. The Board appointed M/s. Rampurawala Mohammed A & Co as Cost Auditors for a fee of ₹2.50 lakh plus applicable tax and out-of-pocket expenses. This appointment is subject to shareholder approval via an ordinary resolution.

Shareholders of Supriya Lifescience have approved the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a term of three years.

The special resolution was passed with a requisite majority through remote e-voting conducted between July 23, 2026 and August 21, 2026. Mr. Sawant’s tenure will run from May 26, 2026 to May 25, 2029.

Voting Results

The company received votes from 361 shareholders representing 58,281,483 shares out of a total outstanding equity base of 80,482,800 shares as on the record date of July 17, 2026. This represents a participation rate of 72.41%.

Promoter group shareholders voted unanimously in favor, casting all 54,967,715 polled votes toward the resolution. Public institutional investors showed strong support with 94.38% of their polled votes in favor, while public non-institutional shareholders supported the resolution at 98.16%.

What the Numbers Show

The voting pattern highlights a clear divergence in engagement levels between promoter and public shareholders. While promoters achieved near-total participation (100% of held shares voted), public non-institutional shareholders participated at less than 1%, casting only 146,673 votes against their holding of over 16 million shares. Despite this low turnout from retail non-institutional holders, the overwhelming support from promoters and institutions ensured the resolution passed with 99.69% affirmative votes.